Adagene Financials
ADAG Stock | USD 1.84 0.01 0.54% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Current Ratio | 6.78 | 4.15 |
|
|
Investors should never underestimate Adagene's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Adagene's cash flow, debt, and profitability to make informed and accurate decisions about investing in Adagene.
Net Income |
|
Adagene | Select Account or Indicator |
Understanding current and past Adagene Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Adagene's financial statements are interrelated, with each one affecting the others. For example, an increase in Adagene's assets may result in an increase in income on the income statement.
Adagene Stock Summary
Adagene competes with Aerovate Therapeutics, Acrivon Therapeutics,, Rezolute, AN2 Therapeutics, and Anebulo Pharmaceuticals. Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company was incorporated in 2011 and is headquartered in Suzhou, China. Adagene Inc operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 259 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | US0053291078 |
CUSIP | 005329107 |
Location | China |
Business Address | Building C14, Suzhou, |
Sector | Biotechnology |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.adagene.com |
Phone | 86 512 8777 3632 |
Currency | USD - US Dollar |
Adagene Key Financial Ratios
Return On Equity | -0.46 | ||||
Operating Margin | (45.35) % | ||||
Price To Sales | 99.86 X | ||||
Revenue | 18.11 M | ||||
Gross Profit | 10.18 M |
Adagene Key Balance Sheet Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Total Assets | 84.3M | 189.5M | 152.4M | 115.7M | 133.1M | 128.7M | |
Other Current Liab | 8.5M | 14.8M | 22.2M | 19.7M | 22.7M | 14.1M | |
Net Tangible Assets | (57.0M) | (89.4M) | 156.6M | 83.1M | 95.6M | 100.3M | |
Net Debt | (67.2M) | (166.9M) | (115.8M) | (87.6M) | (78.9M) | (82.8M) | |
Retained Earnings | (105.7M) | (178.8M) | (258.8M) | (277.8M) | (250.0M) | (237.5M) | |
Accounts Payable | 1.8M | 3.3M | 3.7M | 3.1M | 3.6M | 2.4M | |
Cash | 75.2M | 174.4M | 143.8M | 109.9M | 126.4M | 112.2M | |
Other Assets | 3.1M | 69.3K | 109.6K | 1.0 | 0.9 | 0.86 | |
Net Receivables | 132.4K | 7.5M | 619.4K | 222.0K | 199.8K | 189.8K | |
Other Current Assets | 3.8M | 4.1M | 4.9M | 3.3M | 3.8M | 3.4M | |
Total Liab | 173.7M | 33.0M | 69.3M | 45.2M | 40.7M | 77.3M | |
Net Invested Capital | (81.4M) | 164.0M | 110.9M | 92.5M | 106.4M | 111.7M | |
Short Long Term Debt | 5.0M | 4.5M | 13.6M | 8.4M | 9.7M | 6.4M | |
Total Current Assets | 79.1M | 186.0M | 149.3M | 113.4M | 130.5M | 125.3M | |
Capital Stock | 1.9K | 5.6K | 5.5K | 5.5K | 6.4K | 4.0K | |
Net Working Capital | 63.0M | 156.1M | 94.2M | 82.0M | 94.3M | 97.8M | |
Short Term Debt | 5.0M | 4.5M | 13.8M | 8.6M | 9.9M | 6.5M | |
Common Stock | 1.9K | 5.6K | 5.5K | 5.5K | 6.4K | 4.0K | |
Long Term Debt | 3.0M | 3.0M | 14.1M | 13.5M | 15.6M | 16.3M |
Adagene Key Income Statement Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Ebit | (42.2M) | (71.1M) | (78.8M) | (16.2M) | (14.5M) | (15.3M) | |
Ebitda | (41.3M) | (70.0M) | (77.4M) | (15.0M) | (13.5M) | (14.1M) | |
Net Income | (16.4M) | (73.2M) | (80.0M) | (18.9M) | (17.1M) | (17.9M) | |
Income Tax Expense | 3.2K | 1.7M | 459.1K | 1.7M | 1.9M | 2.0M |
Adagene Key Cash Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Investments | 8M | (2.5M) | (686.0K) | (77.4K) | (89.0K) | (84.5K) | |
Change In Cash | (17.4M) | 99.2M | (30.6M) | (33.8M) | (30.4M) | (28.9M) | |
Free Cash Flow | (29.5M) | (45.9M) | (49.3M) | (28.5M) | (25.7M) | (27.0M) | |
Depreciation | 858.4K | 1.1M | 1.4M | 1.2M | 1.4M | 1.2M | |
Other Non Cash Items | 645.0K | (9.9K) | (2.5M) | (1.4M) | (1.3M) | (1.4M) | |
Capital Expenditures | 935.2K | 2.5M | 690.9K | 85.0K | 97.8K | 92.9K | |
Net Income | (42.4M) | (73.2M) | (80.0M) | (18.9M) | (17.1M) | (17.9M) | |
End Period Cash Flow | 75.2M | 174.4M | 143.8M | 109.9M | 126.4M | 112.2M |
Adagene Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Adagene's current stock value. Our valuation model uses many indicators to compare Adagene value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Adagene competition to find correlations between indicators driving Adagene's intrinsic value. More Info.Adagene is rated below average in return on equity category among its peers. It is rated third in return on asset category among its peers . At this time, Adagene's Return On Equity is most likely to slightly decrease in the upcoming years. Comparative valuation analysis is a catch-all technique that is used if you cannot value Adagene by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Adagene Systematic Risk
Adagene's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Adagene volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Adagene correlated with the market. If Beta is less than 0 Adagene generally moves in the opposite direction as compared to the market. If Adagene Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Adagene is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Adagene is generally in the same direction as the market. If Beta > 1 Adagene moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Adagene Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Adagene's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Adagene growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Adagene January 18, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Adagene help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Adagene. We use our internally-developed statistical techniques to arrive at the intrinsic value of Adagene based on widely used predictive technical indicators. In general, we focus on analyzing Adagene Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Adagene's daily price indicators and compare them against related drivers.
Information Ratio | (0.01) | |||
Maximum Drawdown | 41.45 | |||
Value At Risk | (8.33) | |||
Potential Upside | 6.39 |
Complementary Tools for Adagene Stock analysis
When running Adagene's price analysis, check to measure Adagene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adagene is operating at the current time. Most of Adagene's value examination focuses on studying past and present price action to predict the probability of Adagene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adagene's price. Additionally, you may evaluate how the addition of Adagene to your portfolios can decrease your overall portfolio volatility.
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Stocks Directory Find actively traded stocks across global markets | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |